Published Date : 2023-10-22
Published Date : 2023-10-22
Updated On : 2024-08-08
Pages : 158
Thelansis’s “Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Advanced or metastatic gastroesophageal junction adenocarcinoma, often referred to as GEJ adenocarcinoma, represents a particularly challenging and aggressive cancer subtype. This malignancy originates in the cells lining the junction between the stomach and the esophagus, known as the gastroesophageal junction (GEJ). The tumor's epicenter is situated within the GEJ region in this type of carcinoma. GEJ adenocarcinoma is associated with a substantial clinical burden due to its high propensity for advancing to later stages and its generally poor prognosis. The disease's progression to an advanced or metastatic state intensifies the challenges patients and healthcare providers face. Metastatic GEJ adenocarcinoma implies that the cancer has spread from its initial site to other body parts, significantly reducing the chances of successful treatment and long-term survival. Most patients diagnosed with GEJ adenocarcinoma present with advanced stages of the disease. Subtle or nonspecific symptoms in the early stages frequently lead to delayed diagnosis. Consequently, the potential for successful curative treatment diminishes, and many patients are left with limited treatment options. Factors contributing to the advanced presentation include the tumor's aggressive nature and tendency to remain asymptomatic until later stages. The Siewert classification is an essential framework medical professionals use to categorize adenocarcinomas located within 5 cm of the GEJ. This classification system divides GEJ adenocarcinomas into three distinct types, each with unique characteristics and anatomical locations:
Diagnosing advanced or metastatic gastroesophageal junction adenocarcinoma involves a combination of clinical evaluation, imaging techniques, and often histopathological confirmation. The treatment approach for advanced or metastatic gastroesophageal junction adenocarcinoma is often multidisciplinary and depends on factors like the tumor's stage, location, patient's overall health, and individual preferences.
North America- the United States and Canada
Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Other countries- Japan & China
This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.
KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs
- Data Inputs with sourcing
- Market Event and Product Event
- Country-specific Forecast Model
- Market uptake and patient share uptake
- Attribute Analysis
- Analog Analysis
- Disease burden and pricing scenario
- Summary and Insights
Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.
The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.
Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.
This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.
S. no | Asset | Company | Stage |
1 | Tislelizumab | BeiGene | Phase 3 |
2 | CS1001 | CStone Pharmaceuticals | Phase 3 |
3 | AK129 | Akeso | Phase 1/2 |
4 | ASKB589 | AskGene Pharma, Inc. | Phase 3 |
5 | IBI343 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
6 | Tucatinib and Disitamab vedotin | Seagen Inc. | Phase 1/2 |
7 | EO-3021 | Elevation Oncology, Inc. | Phase 1 |
8 | BBI608 | Sumitomo Pharma America, Inc. | Phase 3 |
9 | AZD0901 | AstraZeneca | Phase 3 |
10 | M108 | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Phase 3 |
Continued...
KOLs across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
COUNTRY | No. Of KOLs |
USA | 17 |
GERMANY | 4 |
UK | 4 |
SPAIN | 3 |
FRANCE | 2 |
ITALY | 3 |
JAPAN | 3 |
CHINA | 4 |
Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
1. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma – Key Findings Summary |
1.1. Clinical findings |
1.1.1. Disease overview |
1.1.2. Therapeutic practices |
1.1.3. Future outlook |
1.2. Commercial findings |
1.2.1. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma market scenario 2023 |
1.2.2. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma market scenario 2028 |
1.2.3. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma market scenario 2033 |
2. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Overview |
2.1. Disease Introduction |
2.2. Pathophysiology |
2.3. Signs and Symptoms |
2.4. Risk Factors |
2.5. Etiology |
2.6. Classification |
2.7. Pathogenesis |
2.8. Diagnosis |
2.9. Complications |
2.10. Treatment Algorithm |
2.10.1. Treatment in US (guidelines) |
2.10.2. Treatment in EU-5 (guidelines) |
2.10.3. Treatment in Japan (guidelines) |
2.10.4. Treatment in China (guidelines) |
2.11. Treatment Goals for Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
2.12. Referral Patterns |
2.12.1. Referral Scenario in US |
2.12.2. Referral Scenario in EU-5 |
2.12.3. Referral Scenario in Japan |
2.12.4. Referral Scenario in China |
2.13. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Prognosis |
2.14. Healthcare burden |
2.14.1. Healthcare burden in US |
2.14.2. Healthcare burden in EU-5 |
2.14.3. Healthcare burden in Japan |
2.14.4. Healthcare burden in China |
2.15. Unmet Needs in Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma management |
2.16. Market Opportunity for Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
2.17. KOL Comments on current and upcoming/expected treatment practices in Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
3. Epidemiology |
3.1. Epidemiology Overview |
3.2. Epidemiology by Geography |
3.2.1. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Epidemiology in US (2023-2033) |
3.2.1.1. Incidence of Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
3.2.1.2. Diagnosed cases |
3.2.1.3. Treatable Patient Pool |
3.2.1.4. Epidemiology Trends |
3.2.2. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Epidemiology in EU-5 (2023-2033) |
3.2.2.1. Incidence of Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
3.2.2.2. Diagnosed cases |
3.2.2.3. Treatable Patient Pool |
3.2.2.4. Epidemiology Trends |
3.2.3. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Epidemiology in Japan (2023-2033) |
3.2.3.1. Incidence of Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
3.2.3.2. Diagnosed cases |
3.2.3.3. Treatable Patient Pool |
3.2.3.4. Epidemiology Trends |
3.2.4. Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Epidemiology in China (2023-2033) |
3.2.4.1. Incidence of Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
3.2.4.2. Diagnosed cases |
3.2.4.3. Treatable Patient Pool |
3.2.4.4. Epidemiology Trends |
3.3. Epidemiology Trends (World-wide) |
4. Market Outlook |
4.1. US Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Forecast 2023-2033 |
4.1.1. Market Progression (Futuristic) |
4.1.2. Market Trends and Expectations |
4.1.2.1. Worst case scenario |
4.1.2.2. Base Case Scenario |
4.1.2.3. Best Case Scenario |
4.1.3. Drivers and Barriers |
4.2. UK Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Forecast 2023-2033 |
4.2.1. Market Progression (Futuristic) |
4.2.2. Market Trends and Expectations |
4.2.2.1. Worst case scenario |
4.2.2.2. Base Case Scenario |
4.2.2.3. Best Case Scenario |
4.2.3. Drivers and Barriers |
4.3. France Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Forecast 2023-2033 |
4.3.1. Market Progression (Futuristic) |
4.3.2. Market Trends and Expectations |
4.3.2.1. Worst case scenario |
4.3.2.2. Base Case Scenario |
4.3.2.3. Best Case Scenario |
4.3.3. Drivers and Barriers |
4.4. Germany Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Forecast 2023-2033 |
4.4.1. Market Progression (Futuristic) |
4.4.2. Market Trends and Expectations |
4.4.2.1. Worst case scenario |
4.4.2.2. Base Case Scenario |
4.4.2.3. Best Case Scenario |
4.4.3. Drivers and Barriers |
4.5. Italy Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Forecast 2023-2033 |
4.5.1. Market Progression (Futuristic) |
4.5.2. Market Trends and Expectations |
4.5.2.1. Worst case scenario |
4.5.2.2. Base Case Scenario |
4.5.2.3. Best Case Scenario |
4.5.3. Drivers and Barriers |
4.6. Spain Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Forecast 2023-2033 |
4.6.1. Market Progression (Futuristic) |
4.6.2. Market Trends and Expectations |
4.6.2.1. Worst case scenario |
4.6.2.2. Base Case Scenario |
4.6.2.3. Best Case Scenario |
4.6.3. Drivers and Barriers |
4.7. Japan Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Forecast 2023-2033 |
4.7.1. Market Progression (Futuristic) |
4.7.2. Market Trends and Expectations |
4.7.2.1. Worst case scenario |
4.7.2.2. Base Case Scenario |
4.7.2.3. Best Case Scenario |
4.7.3. Drivers and Barriers |
4.8. China Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market Forecast 2023-2033 |
4.8.1. Market Progression (Futuristic) |
4.8.2. Market Trends and Expectations |
4.8.2.1. Worst case scenario |
4.8.2.2. Base Case Scenario |
4.8.2.3. Best Case Scenario |
4.8.3. Drivers and Barriers |
4.9. Key Expected Milestones (world-wide) Impacting the Market |
5. Competitive Landscape |
5.1. Pipeline Therapies Overview |
5.1.1. Phase III Therapies |
5.1.1.1. Current Status |
5.1.1.2. Trial details, results |
5.1.1.3. Approval Timeline |
5.1.1.4. Likelihood of approval |
5.1.1.5. Expected Product Positioning |
5.1.1.2. All other Phase III Therapies ….. |
5.1.1.3. Attribute Analysis of Phase III molecules |
5.1.2. Phase II and Phase I/II Therapies |
5.1.2.1. Current Status |
5.1.2.2. Trial details, results |
5.1.2.3. Approval Timelines |
5.1.3. List of active Pre-clinical Therapies |
5.1.3.1. Status in Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
5.1.3.2. Company positioning |
5.1.3.2. All other pre-clinical therapies |
5.1.4. List of Inactive/discontinued assets |
5.1.4.1. Business impact of discontinuations on current pipeline |
5.1.5. Potential winners from Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Pipeline |
5.1.5.1. Potential Blockbusters across the pipeline |
6. Regulatory/Approval Scenario |
6.1. Regulatory/Approval Framework in US |
6.1.1. Policy Framework |
6.1.2. Payer Expectations |
6.2. Regulatory/Approval Framework in UK |
6.2.1. Policy Framework |
6.2.2. Payer Expectations |
6.3. Regulatory/Approval Framework in France |
6.3.1. Policy Framework |
6.3.2. Payer Expectations |
6.4. Regulatory/Approval Framework in Germany |
6.4.1. Policy Framework |
6.4.2. Payer Expectations |
6.5. Regulatory/Approval Framework in Italy |
6.5.1. Policy Framework |
6.5.2. Payer Expectations |
6.6. Regulatory/Approval Framework in Spain |
6.6.1. Policy Framework |
6.6.2. Payer Expectations |
6.7. Regulatory/Approval Framework in Japan |
6.7.1. Policy Framework |
6.7.2. Payer Expectations |
6.8. Regulatory/Approval Framework in China |
6.8.1. Policy Framework |
6.8.2. Payer Expectations |
7. Clinical Trial Assessment – Current and Future Paradigm |
7.1. Distribution of Primary Endpoints across trials |
7.2. Distribution of Secondary Endpoints across trials |
7.3. Evolution and acceptance of surrogate endpoints |
7.4. Key Investigator initiated trials |
7.5. Attrition analysis |
7.5.1. Suspended/Discontinued Assets |
7.5.2. Failed Trials, Reasons and Business Impact |
7.5.3. Terminated Trials, Reasons and Business Impact |
7.5.4. Withdrawn Trials, Reasons and Business Impact |
7.6. Trial enrollment scenario and challenges |
7.7. Clinical Trial Guidance (across geographies) |
8. Thelansis Commentary |
8.1. Key Unmet needs in Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma |
8.2. Possible Best-case Clinical Trial Strategies |
8.3. Possible Best Case Targeted Product Profile (TPP) |
8.4. Possible Best-case Market positioning strategies |
8.5. Possible Best-case Market Access Strategies |
8.6. Possible Best-case LCM Strategies |
8.7. Overall View on Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma Market in Dollar Value |
9. Report Methodology |
9.1. Secondary research |
9.2. Primary research |
9.3. Data collation |
9.4. Insight Generation |
10. About Thelansis |
10.1. Our Capabilities |
10.2. Our Services |
10.3. Our Contacts |
10.4. Disclaimer |